Related Interviews

Three Large-Cap Biotechs That Stand Out in an Uncertain Market
April 06, 2023
Singh, Hartaj

Sizing Up Risk Across the Biotech Cap Spectrum
August 18, 2022
Singh, Hartaj

Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
September 30, 2020
Singh, Hartaj

Innovation Continues to Be Strong Despite Volatility in Biotech Sector
March 20, 2020
Zhong, Yun

Several Readouts on Allogeneic Cell Therapy Expected in 2020
March 20, 2020
Prasad, Raju

Outperforming Over a Full Market Cycle with Less Volatility
December 13, 2019
Benowitz, Jason

Taking a Defensive Position in Anticipation of a Correction
June 28, 2019
Stonehouse, David

Being More Selective and Focusing on Data in the Gene Therapy Space
April 05, 2019
Amusa, Gbola

Major Pharmas Becoming Increasingly Comfortable with Gene Therapy
March 22, 2019
Zhong, Yun

Clinical Data and M&A Serve as Catalysts in 2019
March 22, 2019
Roy, Soumit

Big Pharma Looking to Small-Cap Biotechs for Innovation
March 15, 2019
Vandermosten, John

The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj

Gene Therapy Companies with Better Clinical Data and Benefits Likely to Do Well
October 02, 2018
Yang, Difei

Data Consistency is Important When Investing in Gene Therapy
March 21, 2018
Chattopadhyay, Debjit

Good Management Teams and Good Science are Creating Opportunities in Biotech
March 08, 2018
Singh, Hartaj

Biotech Space Lining Up for New Product Cycle
April 21, 2017
Singh, Hartaj

Critical Demand for Innovation in Pharma and Biotech
August 12, 2016
Brozak, Steve

Biotechnology Capital Inflows Reach Historic Highs
April 07, 2014
Skorney, Brian

Increased Biotech Productivity and Innovation Reflected in FDA-Approved Drugs
August 23, 2013
Tenthoff, Ted

Investing in Health Care Innovation
April 30, 2013
Kuruvilla, Finny

FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market
April 08, 2013
Skorney, Brian